UBS Group’s Halozyme HALO Stock Holding History

UBS Group’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-278,000	Closed	-$7.45M	–	8167
2020 Q2	$7.45M	Buy	278,000 +268,100	+2,708%	+$6.05M	﹤0.01%	1739
2020 Q1	$178K	Sell	9,900 -78,900	-89%	-$1.5M	﹤0.01%	4812
2019 Q4	$1.57M	Buy	+88,800	New	+$1.54M	﹤0.01%	3789
2017 Q1	–	Sell	-19,500	Closed	-$193K	–	7765
2016 Q4	$193K	Buy	+19,500	New	+$214K	﹤0.01%	4809
2016 Q2	–	Sell	-163,300	Closed	-$1.55M	–	7820
2016 Q1	$1.55M	Buy	+163,300	New	+$1.54M	﹤0.01%	2894
2015 Q3	–	Sell	-80,000	Closed	-$1.81M	–	8498
2015 Q2	$1.81M	Sell	80,000 -80,000	-50%	-$1.41M	﹤0.01%	3076
2015 Q1	$2.29M	Buy	+160,000	New	+$2.31M	﹤0.01%	2813

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

UBS Group's HALO Position: Q2 2026 in Review

UBS Group increased its Halozyme (HALO) stake by 63% in Q2 2026, buying an estimated $39.4M and bringing the position to 1,492,224 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1013.

UBS Group first reported a position in HALO in Q4 2014 and has held it in 47 quarters since. The position peaked at $216M in Q3 2025. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

UBS Group held 1,492,224 shares of Halozyme worth $117M as of Q2 2026.
UBS Group bought 578,221 Halozyme shares in Q2 2026, an estimated $39.4M.
Halozyme made up 0.01% of UBS Group's portfolio in Q2 2026, its #1013 holding.
UBS Group first reported a position in Halozyme in Q4 2014 and has held it in 47 quarters since.
UBS Group's Halozyme position peaked at $216M in Q3 2025.
672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.